diff --git a/pages/STOP2030___Web___Posts.md b/pages/STOP2030___Web___Posts.md
index 8e91bbbe..b58c7dd7 100644
--- a/pages/STOP2030___Web___Posts.md
+++ b/pages/STOP2030___Web___Posts.md
@@ -15,25 +15,16 @@
 	  
 	  #+END_VERSE
 	- #
-	- # The REALISE clinical trial is registered
+	- ## Re The REALISE clinical trial is registered
 	  
 	  At STOP2030, we aim to provide a pharmacological tool that aids in achieving the WHO's goals for
 	  soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on [clinicaltrials.gov](https:/clinicaltrials.gov/study/NCT06282315__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncW8CTAdM$) and the [Pan African Clinical Trial
 	  Registry](https:/pactr.samrc.ac.za/Search.aspx__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncACmxOT0$) (id number PACTR202402529220760).
 	  
 	  This randomized control trial is a Cohort Event Monitoring study designed to evaluate the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large
-	  populations, compared to the standard dose of albendazole currently used against STH. We plan to recruit around 20,000 school-aged children between 5 and 17 years old in Kenya and Ghana, starting in July 2024.
-	  
-	  
-	  
-	  The general goals of the REALISE
-	  study are to validate the benefits of the FDC through this pragmatic trial
-	  within the context of a mass drug administration (MDA) program, to evaluate
-	  safety as a primary endpoint, and effectiveness profile as a secondary
-	  endpoint, in a large population of school-aged children.
-	  
-	  
+	  populations, compared to the standard dose of albendazole currently used against STH. We plan to recruit around 20,000 school-aged children between 5 and 17 years old in Kenya and Ghana, starting the the second semester of 2024.
 	  
+	  The general goals of the REALISE study are to validate the benefits of the FDC through this pragmatic trial within the context of a mass drug administration (MDA) program, to evaluate safety as a primary endpoint, and effectiveness profile as a secondary endpoint, in a large population of school-aged children.
 	  The clinical trial will have two
 	  arms, randomized by school. One arm will receive a single dose of the
 	  fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and